Prospects for immunotherapeutic proteolytic antibodies.
Monoclonal antibodies are suitable for therapeutic applications by virtue of their excellent target binding characteristics (specificity, affinity) and long half-life in vivo. Catalytic antibodies (CAbs) potentially represent a new generation of therapeutics with enhanced antigen inactivation capability. Here, we describe prospects for development of therapeutic CAbs to the envelope protein gp120 of HIV. The strategy consists of exploiting the natural tendency of the immune system to synthesize germline-encoded, serine protease-like CAbs. Lupus patients were found to develop antibodies to a conserved component of the CD4 binding site of gp120, potentially offering a means to obtain human antibodies expressing broad reactivity with various HIV strains. Covalently reactive antigen analogs (CRAs) capable of selective recognition of nucleophilic Abs were synthesized and applied to isolate Fv and L chain catalysts from lupus phage repertoires. CRA binding by the recombinant Ab fragments was statistically correlated with catalytic cleavage of model peptide substrates. A peptidyl CRA composed of residues 421-431 with a phosphonate diester moiety at its C terminus was validated as a reagent that combines noncovalent and covalent binding interactions in recognition of a gp120ase L chain. A general challenge in the field is the apparent instability of the catalytic conformation of the Abs. In reference to therapy of HIV infection, assurance is required that the Abs recognize the native conformation of gp120 expressed as a trimer on the virus surface.
Zhou
Yong-Xin
YX
Chemical Immunology and Therapeutics Research Center, Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, 6431 Fannin, Houston, TX 77030, USA.
Karle
Sangeeta
S
Taguchi
Hiroaki
H
Planque
Stephanie
S
Nishiyama
Yasuhiro
Y
Paul
Sudhir
S
D017151:Antibodies, Catalytic / Q000378:metabolism / Q000627:therapeutic use*; D010450:Endopeptidases / Q000378:metabolism / Q000627:therapeutic use*; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
D017151:Antibodies, Catalytic; D015699:HIV Envelope Protein gp120; D010450:Endopeptidases